ClinicalTrials.gg
CompletedNCT01337804Updated Feb 23, 2015

A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)

A Phase 1 interventional study of omeprazole/sodium bicarbonate and omeprazole magnesium in Heartburn, sponsored by Bayer. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-23.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study compares the bioequivalence of omeprazole administered as either Zegerid® powder for oral suspension 20 mg or as Prilosec 40 mg capsule to healthy participants.

02

Conditions studied

  • Heartburn

Browse trials for

03

In context

Heartburn

154 studies on the registry are indexed under Heartburn; 12 are open to participants now.

This study's enrollment of 50 is below the median of 100 across 127 interventional studies indexed under Heartburn.

Browse Heartburn studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is of non-Asian origin.
  • Female participants of must have a negative pregnancy test and agree to use (and/or have their partner use) two acceptable methods of beginning at the screening visit, throughout the study, and until 2 weeks after the last dose of study drug.
  • Participant has a (BMI) ≤35 kg/m2 at the screening visit.
  • Participant is judged to be in good health.
  • Participant has no abnormality on (ECG).
  • Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • Participant is mentally or legally incapacitated, has significant emotional problems at the time of screening visit or has a history of a psychiatric disorder over the last 5 to 10 years. Participants who have had situational depression may be enrolled in the study at the discretion of the investigator.
  • Participant has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  • Participant has taken any gastric antisecretory drugs (e.g., histamine receptor type-2 antagonists [H2RAs] or proton pump inhibitors [PPIs]), antacids, or any other prescription or over- the-counter (OTC) medications within 14 days prior to Period 1 and during the trial.
  • Participant has been treated with any trial drug or therapy, or participated in a clinical trial in the 30 days prior to Period 1.
  • Participant has any laboratory test result prior to dosing in Period 1 deviating from the normal reference ranges established by the local laboratory by more than 20% that the investigator judges to be of possible clinical significance.
  • Participant has an estimated of ≤80 mL/min based on the Cockcroft-Gault equation.
  • Participant has a history of stroke, chronic seizures, or major neurological disorder.
  • Participant has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases. Participants with a history of uncomplicated kidney stones or childhood asthma may be enrolled in the study at the discretion of the investigator.
  • Participant has a history of neoplastic disease.
  • Participant is a nursing mother.
  • Participant has any history or serologic evidence of or C with abnormal liver function tests (except for benign, self-limited hepatitis A >5 years prior to randomization), hepatic or biliary tract disease, or a history of gastrointestinal tract surgery.
  • Participant has an allergy or to any component/ of the study drugs, has a history of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food.
  • Participant is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies (such as St. John's Wort [hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods), until the telephone follow-up. There may be certain medications that are permitted. Participants must be explicitly warned of the potential risk of taking erythromycin, clarithromycin, nefazodone, ketoconazole, itraconazole, cyclosporine, and (HIV)protease inhibitors during the study.
  • Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses per day of alcoholic beverages (1 glass is approximately equivalent to: 10 ounces of beer, 4 ounces of wine, or 1 ounce of distilled spirits).
  • Participant has consumed grapefruit juice, grapefruits and grapefruit products within 2 weeks prior to administration of the initial dose of study drug, and does not agree to refrain from their consumption throughout the study (including the interval between treatment periods) and until the telephone follow-up.
  • Participant consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, chocolate, or other caffeinated beverages per day.
  • Participant has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another study within 30 days prior to Period 1. The 4-week window will be derived from the date of the last study procedure (i.e., telephone follow-up) in the previous study to the screening visit of the current study.
  • Participant is currently a regular user (including "recreational use") of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 1 year.
  • There is any concern by the investigator regarding the safe participation of the participant in the study or for any other reason; the investigator considers the participant inappropriate for participation in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Zegerid-Prilosec

    Participants receive Zegerid in Period 1 and Prilosec in Period 2, with a 10- to 21-day washout between study drug administrations.

    Drug: omeprazole/sodium bicarbonate · Drug: omeprazole magnesium

  • Experimental
    Prilosec-Zegerid

    Participants receive Prilosec in Period 1 and Zegerid in Period 2, with a 10- to 21-day washout between study drug administrations.

    Drug: omeprazole/sodium bicarbonate · Drug: omeprazole magnesium

Interventions

  • Drugomeprazole/sodium bicarbonate

    Drug pages: Omeprazole · Sodium Bicarbonate

    Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension

    Also known as: Zegerid Powder for Oral Suspension

  • Single 40 mg capsule of omeprazole given orally

    Also known as: Prilosec

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from 0 to infinity (AUC[0-∞])

    Time frame: Up to 12 hours post-dose

  2. Maximum plasma concentration (Cmax)

    Time frame: Up to 12 hours post-dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2011
First posted
Apr 19, 2011
Start
Jan 2011
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Last update
Feb 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01337804
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 19, 2011
Start date
Jan 2011
Primary completion
Jan 2011
Completion
Jan 2011
Last update
Feb 23, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Omeprazole · Sodium Bicarbonate

Start the discussion